Celldex Therapeutics
CLDX
185 hedge funds and large institutions have $1.99B invested in Celldex Therapeutics in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 60 reducing their positions, and 22 closing their positions.
205% more call options, than puts
Call options by funds: $2.29M | Put options by funds: $750K
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
38% more capital inflows, than outflows
Capital inflows: $231M | Capital outflows: $167M
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
3.34% more ownership
Funds ownership: 106.51% → 109.85% (+3.3%)
1% more funds holding
Funds holding: 184 → 185 (+1)
5% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$60M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$33.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.6M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$14.2M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$56.2M |
| 2 |
CC
Commodore Capital
New York
|
-$12.2M |
| 3 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
-$9.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.03M |
| 5 |
Polar Capital Holdings
London,
United Kingdom
|
-$7.7M |
CLDX Hedge Fund Activity: Q4 2025 in Review
185 of the 8,287 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2025, worth a combined $1.99B — up 8.9% from $1.83B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CLDX positions and 22 closed out — a net gain of 3 holders — while 57 added to existing stakes and 60 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $60M. The largest seller was Point72 Asset Management, cutting an estimated $56.2M.
- 185 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2025, up from 184 in Q3 2025.
- Funds reported $1.99B of Celldex Therapeutics stock for Q4 2025, up 8.9% quarter-over-quarter.
- 25 funds opened new Celldex Therapeutics positions in Q4 2025 and 22 closed out, a net change of +3 holders.
- The largest Celldex Therapeutics buyer in Q4 2025 was Wellington Management Group, an estimated $60M added.
- The largest Celldex Therapeutics seller in Q4 2025 was Point72 Asset Management, an estimated $56.2M sold.
Based on aggregated 13F filings for Q4 2025.